Browsing Tag
Pharming Group
3 posts
Pharming Group tightens 2026 revenue guidance to $380m–$390m after strong third-quarter sales
Pharming Group Q3 revenue rises 21% to $117.6 million as Joenja sales jump 58%. Explore revised guidance, expenses and investor outlook.
Joenja moves closer to broader pediatric APDS label as Pharming Group builds second growth franchise
Pharming Group wins FDA Priority Review for lower-dose Joenja in children with APDS as the fast-growing rare-disease franchise expands.
Why Joenja’s pediatric expansion could strengthen Pharming Group’s long-term commercial runway
Find out how Pharming’s Joenja FDA review could affect PHAR stock sentiment, pediatric APDS access, and rare-disease revenue growth.